Comparative Pharmacology
Head-to-head clinical analysis: FLO PRED versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLO PRED versus FLUDROCORTISONE ACETATE.
FLO-PRED vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit phospholipase A2, decreasing prostaglandin and leukotriene synthesis.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Initial: 5-60 mg orally daily in divided doses; maintenance: 5-15 mg orally daily. Also available as ophthalmic suspension (1 drop 2-4 times daily).
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
The terminal elimination half-life of prednisolone is approximately 2-4 hours (mean ~3 hours) in adults with normal hepatic function. This short half-life allows for once-daily or alternate-day dosing to minimize adrenal suppression.
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
FLO-PRED (prednisolone acetate) is primarily eliminated via hepatic metabolism, with inactive metabolites excreted renally. Approximately 20-30% of a dose is excreted unchanged in urine, and less than 5% is eliminated via biliary/fecal routes.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid